FDA approves Reblozyl to treat anemia associated with lower-risk myelodysplastic syndromes. BMS + Acceleron
Bristol Myers Squibb and Acceleron Pharma Inc. announced the FDA has approved Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent (EMA), for the treatment of anemia failing… read more.